Alector, Inc.
NASDAQ:ALECBiotechnology
+$0.08 today
- Market cap
- $382.61M
- Beta
- 0.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.13
Volume 2.13M
Average 0.65M
ALEC Sales of Investments
Cash received from selling or redeeming investments.
Alector, Inc.NASDAQ: ALEC
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $112.87M fell 7.1% year over year, ahead of the -10.3% change in trailing-twelve-month sales of investments. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Sales of investments amounted to 2226.3% of revenue in FY2025, up 1653.3 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -7.1% holds above the trailing-twelve-month pace of -10.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 468.52M USD
- Year-over-year change
- -18.7%
- 4-year CAGR
- +12.1%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 468.52M | -18.7% |
| FY2024 | 2024-12-31 | 576.13M | -12.2% |
| FY2023 | 2023-12-31 | 656.03M | +63.2% |
| FY2022 | 2022-12-31 | 402M | +35.4% |
| FY2021 | 2021-12-31 | 296.99M | — |
Sales of Investments vs competitors
How ALEC compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.3% is the 3rd highest of 8, against a peer median of -28.1%.
- Sales of investments amounts to 2496.8% of revenue for ALEC, versus a peer median of 2153.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $459.84M USD | -10.3% | +5.2% | 2496.8% | |
| LTM Mar 2026 | $335.26M USD | +13.7% | +11.1% | — | |
| LTM Mar 2026 | $271.96M USD | -14.9% | -19.9% | 4305.9% | |
| LTM Mar 2026 | $138.92M USD | +29.2% | +11.5% | — | |
| LTM Mar 2026 | $135.28M USD | -45.1% | +28.6% | — | |
| LTM Mar 2026 | CHF 103.25M CHF | -59.1% | -11.6% | — | |
| LTM Mar 2026 | $82M USD | -28.1% | — | — | |
| LTM Mar 2026 | $18.31M USD | -65.5% | -48.9% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ALEC) | — | -28.1% | -0.3% | 2153.0% | |
Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.33M) | (133.31M) | (130.39M) | (119.05M) | (142.93M) |
| Depreciation & Amortization | 8.32M | 8.47M | 8.85M | 8.84M | (861K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.79M | 46.15M | 42.8M | 39.46M | 26.66M |
| Change in Working Capital | 283.68M | 59.53M | (90.15M) | (146.99M) | (74.06M) |
| Accounts Receivables | (7.39M) | 4.8M | 2.59M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.92M | (572K) | (377K) | (1.44M) | (524K) |
| Other Working Capital | 289.16M | 55.29M | (92.36M) | (145.55M) | (73.53M) |
| Other Non-Cash Items | 2.1M | (1.16M) | (15.27M) | (12.17M) | 7.16M |
| Operating Cash Flow | 298.55M | (20.33M) | (184.16M) | (229.91M) | (184.03M) |
| Capital Expenditures | (3.25M) | (4.12M) | (2.38M) | (1.26M) | (41K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (343.4M) | (556.9M) | (551.73M) | (467.74M) | (271.88M) |
| Sales of Investments | 296.99M | 402M | 656.03M | 576.13M | 468.52M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (49.66M) | (159.01M) | 101.92M | 107.13M | 196.6M |
| Debt Repayment | 0 | 0 | 0 | 9.39M | 0 |
| Common Stock Issued | 0 | 4.51M | 2.55M | 71.11M | 20M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30.3M | 0 | 0 | 1.04M | 217K |
| Financing Cash Flow | 30.3M | 4.51M | 2.55M | 81.54M | 20.22M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 279.18M | (174.83M) | (79.69M) | (41.23M) | 32.78M |
| Free Cash Flow | 295.3M | (24.45M) | (186.54M) | (231.16M) | (184.07M) |
Alector, Inc.
NASDAQ:ALEC
Intrinsic Alpha fair value
Locked
Current Price
$2.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.